InvestorsHub Logo
Followers 4
Posts 1242
Boards Moderated 0
Alias Born 01/16/2016

Re: None

Wednesday, 02/03/2016 3:13:41 PM

Wednesday, February 03, 2016 3:13:41 PM

Post# of 6602
Factors are beginning to stack up. Between the dilution caused by the acquisition and the seeking alpha short attack, this stock his highly undervalued. It may be that it is being held down by manipulation too. Add onto this that the company decides to spend pretty much ever dollar it makes on research and patents. In this way,the top-line of the company may be very high, but very little money is reaching down to the bottom-line earnings per share. While at first glance it seems like spending money is hurting Ekso, I think the research thy are doing is worth it. Ekso may set the bar high enough so that it's very difficult for competitors to reach. They are the only ones doing 'high intensity training' to my knowledge, not just taking the user for a ride. Also think about it from the perspective of the FDA. If you have one company that has by far the most data and recorded steps, it's hard not to approve them first. I do think the FDA is being extraordinary slow to approve given that the technology is physical, and not a drug. On the other hand, if they FDA standards were lower - these really cheap knock off companies will suddenly have a leg up. I think it's to the credit of the FDA and to the benefit of Ekso that they have kept the requirements high.

Once again, I own Ekso stock long. (7853 shares at .9606 cost basis)
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EKSO News